First Manhattan
ITCI

First Manhattan’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

First Manhattan’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-118,618
Closed -$3.04M – 1479
2020
Q2 		$3.04M Sell
118,618
-79,082
-40% -$1.6M 0.02% 261
2020
Q1 		$3.04M Buy
+197,700
New +$4.29M 0.02% 257

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

First Manhattan's ITCI Position: Q3 2020 in Review

First Manhattan sold out of Intra-Cellular Therapies Inc. (ITCI) in Q3 2020, closing a stake of 118,618 shares — an estimated $3.04M sold.

First Manhattan first reported a position in ITCI in Q1 2020 and held it in 2 quarters. The position peaked at $3.04M in Q2 2020. 176 funds tracked by Wall St. Rank hold ITCI as of Q3 2020.

  • First Manhattan reported no remaining Intra-Cellular Therapies Inc. position as of Q3 2020 after selling out during the quarter.
  • First Manhattan sold 118,618 Intra-Cellular Therapies Inc. shares in Q3 2020, an estimated $3.04M.
  • First Manhattan first reported a position in Intra-Cellular Therapies Inc. in Q1 2020 and held it in 2 quarters.
  • First Manhattan's Intra-Cellular Therapies Inc. position peaked at $3.04M in Q2 2020.
  • 176 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q3 2020.

Based on First Manhattan's 13F filing for Q3 2020, filed 12 Nov 2020.